{"data":{"id":1636,"lang":"en","title":"BioNTech Autogene Cevumeran mRNA Vaccine Keeps 87.5% of Pancreatic Cancer Responders Alive at Six Years, Versus 13% Standard Survival in MSK Phase 1 Update","summary":"Memorial Sloan Kettering reports 87.5% of immune responders to BioNTech autogene cevumeran mRNA pancreatic cancer vaccine still alive 4-6 years post-surgery.","category":"science","category_label":"Science","published_at":"2026-05-12T18:03:07Z","updated_at":"2026-05-12T18:03:07Z","url":"https://techtools.cz/tools/news/article/1636-biontech-autogene-cevumeran-mrna-vaccine-keeps-87-5-of-pancreatic-cancer","api_url":"https://techtools.cz/news-api/v1/articles/1636?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/1636.md?lang=en","image_url":"https://images.unsplash.com/photo-1576091160399-112ba8d25d1d?w=800","word_count":138,"reading_time_minutes":1,"sources":[{"url":"https://www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out","domain":"mskcc.org"},{"url":"https://www.npr.org/2026/05/12/nx-s1-5783797/pancreatic-cancer-breakthroughs-daraxonrasib-mrna","domain":"npr.org"}],"translation":{"lang":"cs","id":1709,"title":"mRNA vakcína BioNTechu autogene cevumeran udržela 87,5 % respondérů s rakovinou slinivky naživu po šesti letech, oproti standardním 13 % v aktualizaci fáze 1 z MSK","url":"https://techtools.cz/tools/news/clanek/1709-mrna-vakcina-biontechu-autogene-cevumeran-udrzela-87-5-responderu-s-rakovinou","api_url":"https://techtools.cz/news-api/v1/articles/1709?lang=cs"},"content":"Memorial Sloan Kettering Cancer Center's updated Phase 1 results show 7 of 8 immune responders (87.5%) to BioNTech's personalized mRNA vaccine autogene cevumeran (BNT122) remain alive 4 to 6 years after pancreatic cancer surgery, principal investigator Dr. Vinod Balachandran reported. Only 2 of 8 non-responders survived, with a median survival of 3.4 years.\n\nThe 16-patient trial paired the vaccine with chemotherapy and an immunotherapy checkpoint inhibitor. Each vaccine was custom-designed in Germany from the patient's tumor genetics and delivered within nine weeks of surgery. Standard five-year survival for pancreatic cancer sits near 13%, according to the American Cancer Society.\n\nBalachandran called the immune response \"very potent\" with \"exceptional durability.\" BioNTech and Genentech, a member of the Roche Group, are now expanding the work into a larger Phase 2 study after MSK reaffirmed the data on April 19, 2026."}}